Dr. Markus Joerger, Cantonal Hospital. St. Gallen, Switzerland
Dr.Markus Joerger is a medical oncologist and clinical pharmacologist, with a focus on early development of anticancer drugs, anticancer drug pharmacokinetics and pharmacogenetics, and therapeutic drug monitoring in oncology. After his graduation from medical school in 1996, he underwent his medical training at the University Hospital Zurich and Cantonal Hospital St.Gallen. From 2003 to 2007, he did his PhD and clinical pharmacology training at the Netherlands Cancer Institute in the group of Professor Jan H.M. Schellens. In December 2007, MARKUS JOERGER published his PhD-thesis on “Pharmacokinetic and pharmacogenetic profiling in solid cancer patients”. Since then, he published over 50 articles, many of them dealing with the pharmacokinetics and pharmacodynamics of the taxanes, 5-fluorouracil or high-dose methotrexate. In his research, drug modeling is often used, to explain interindividual variability of anticancer drug pharmacokinetics, and calculate dosing algorithms implementing specific patient characteristics and/or therapeutic drug monitoring. Mark Joerger works in the Division of Medical Oncology of the Cantonal Hospital St.Gallen, the largest oncology institute in Switzerland. St.Gallen is situated in Eastern Switzerland, 80 km from Zurich. St.Gallen is well known for its two-yearly Breast Cancer Conference. MARKUS JOERGER is married, and has a 4-year of son. His present research projects are mainly collaborative studies with coworkers at the Universities of Basel, Bern, Bonn (Germany), the Netherlands Cancer Institute and Pittsburgh University among others.